Navigation Links
EntreMed Reports Third Quarter 2010 Financial Results
Date:11/12/2010

ROCKVILLE, Md., Nov. 12, 2010 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2010.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

The Company reported a net loss for the third quarter of 2010 of ($2.1 million), or ($0.24) per share. This compares to a reported net income of approximately $85,000 for the same period last year.  Reported net loss for the first nine months of 2010 was ($9.2 million), or ($1.09) per share as compared to ($6.5 million) or ($0.91) per share for 2009.  At September 30, 2009, the Company accrued and recorded estimated royalty revenue from sales of Thalomid® of approximately $3.3 million.  For 2010, royalty revenues will be recorded when they are received, which we expect to occur in the fourth quarter of 2010 and first quarter of 2011.

Kathy Wehmeir-Davis, EntreMed Principle Accounting Officer, commented, "Our financial results for the third quarter are in line with our expectations. Our 2010 research and development expenses increased slightly in the third quarter as we continued to enroll patients in our multi-center Phase 2 ovarian cancer study with ENMD-2076.  At the end of the quarter, we reported approximately $8.4 million in cash and short-term investments.  We believe that these resources, coupled with anticipated royalty inflows, will provide us with sufficient resources to cover planned operations through 2011."

Michael M. Tarnow, Executive Chairman, commented, "As we continue to execute on our strategy to accelerate the clinical development of ENMD-2076, we remain diligent in our cost management efforts as
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Receives Notice of NASDAQ Compliance
2. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
3. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
4. EntreMed Reports Second Quarter 2010 Financial Results
5. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
6. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
9. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
10. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
11. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... A Michigan State University researcher is looking to give ... workout, and her latest research shows that a cyber ... the Games for Health Journal , is the ... still a better motivator during exercise, a software-generated partner ... that something that isn,t real can still motivate people ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
Breaking Medicine News(10 mins):Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... Record Profitability and 12th Consecutive Year of Record ... ... $164 ... ST. LOUIS, Feb. 15 KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated ...
... One day doctors may recommend using high efficiency ... smoking cessation, and exercise to improve cardiovascular health, ... study, they found that using HEPA filters for ... of cardiovascular health in healthy, non-smoking elderly individuals. ...
... single prostate specific antigen (PSA) test at age 50 or ... 25 years later, (regardless of clinical significance) have now found ... prostate cancer. , The findings, published in the online ... men would benefit from intensive screening. , More men die ...
... Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals Inc. ... the close of trading on Thursday, February 21, 2008. ... on or about that date,pending final approvals., Standard ... relevant,updates on its website: http://www.standardandpoors.com ., National ...
... killer, but the recent findings of four Texas A&M University ... the dreaded disease. , Diabetics not only have high ... levels because they have trouble metabolizing glucose and fatty acids. ... acid aspects of diabetes separately because there was nothing linking ...
... Following the,company,s announcement of record unaudited revenues ... nutritional product manufacturer subsidiary InterACTIVE,Nutrition International, Inc., ... Board: NNTN) http://www.naturalnutritioninc.com ,announced today the ... common stock.,Each shareholder will receive one additional ...
Cached Medicine News:Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 2Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 3Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 4Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 5Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 6Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 7Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 8Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 9Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 10Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 11Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 12Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 13Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 14Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 15Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 16Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 17Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 18Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 19Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 20Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 21Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 22Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 23Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Research findings may lead to new ways to study and fight diabetes 2Health News:Research findings may lead to new ways to study and fight diabetes 3Health News:Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year 2
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... an immunometric ('sandwich') EIA for the ... serum or plasma. LH in the ... anti-LH antibodies directed at different epitopes. ... particles and the other is labelled ...
... is a glycoprotein secreted by the anterior ... TSH, the intact LH molecule is a ... glycoproteins all have homologous alpha-subunits, however each ... and FSH production and secretion are stimulated ...
Microwell-EIA for the detection of GAD Autoantibody....
Medicine Products: